Study

A phase I trial of andrographolide in HIV positive patients and normal volunteers. – Cost Effective Supplements

A phase I trial of andrographolide in HIV positive patients and normal volunteers.

Quick navigation


http://www.ncbi.nlm.nih.gov/pubmed/10925397


Conclusion of this study

A significant rise in the mean CD4(+) lymphocyte level of HIV subjects occurred after administration of 10 mg/kg andrographolide (from a baseline of 405 cells/mm(3) to 501 cells/mm(3); p = 0.002). There were no statistically significant changes in mean plasma HIV-1 RNA levels throughout the trial. Andrographolide may inhibit HIV-induced cell cycle dysregulation, leading to a rise in CD4(+) lymphocyte levels in HIV-1 infected individuals.


Supplements analyzed in this study

Chiretta

Health conditions analyzed in this study

No health conditions information for this study.

Functions related to this study

Detox


Slightly Negative
Chiretta


Body systems related to this study


Digestive System
Scroll to top